{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:13:41Z","timestamp":1788527621816,"version":"build-2803163510"},"reference-count":51,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007076","name":"Italian Association for Cancer Research","doi-asserted-by":"publisher","award":["Investigator Grant 2021 (ID 25734)"],"award-info":[{"award-number":["Investigator Grant 2021 (ID 25734)"]}],"id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]},{"award":["Investigator Grant 2021 (ID 25734)"],"award-info":[{"award-number":["Investigator Grant 2021 (ID 25734)"]}],"id":[{"id":"https:\/\/ror.org\/02g2x7380","id-type":"ROR","asserted-by":"publisher"}]},{"name":"PNNR","award":["THE; ECS00000017"],"award-info":[{"award-number":["THE; ECS00000017"]}]},{"name":"PNNR","award":["MCNT1-2023-12377671"],"award-info":[{"award-number":["MCNT1-2023-12377671"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Acquired resistance to targeted therapies is inevitable in EGFR-mutant non-small cell lung cancer (NSCLC), yet the principles governing its emergence in vivo remain incompletely understood. In particular, how lesion-level response patterns vary across distinct EGFR allele contexts during therapy has not been systematically examined at single-lesion resolution. Here, we establish a longitudinal in vivo imaging platform enabling single-lesion resolution tracking of tumor behavior during therapy in genetically engineered mouse models representing clinically relevant EGFR alleles. Using high-resolution micro-computed tomography (micro-CT) and three-dimensional reconstruction, we monitor tumor growth, therapeutic response, and resistance during osimertinib treatment. EGFR genotype is associated with distinct patterns of tumor growth, response kinetics, and resistance timing. Therapeutic response is spatially heterogeneous, with coexisting lesions undergoing complete regression, persistence, or progression within the same lung. During treatment, spatially distinct lesion-level behaviors included persistent growth during therapy and initial regression followed by regrowth. These findings demonstrate the utility of longitudinal micro-CT imaging to investigate allele-associated differences in treatment response and resistance timing at single-lesion resolution in vivo.<\/jats:p>","DOI":"10.3390\/ijms27177727","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:48:36Z","timestamp":1788256116000},"page":"7727","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal In Vivo Imaging at Single-Lesion Resolution Identifies Allele-Associated Response and Resistance Dynamics in EGFR-Mutant Lung Cancer"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3251-1791","authenticated-orcid":false,"given":"Eva","family":"Cabrera San Millan","sequence":"first","affiliation":[{"name":"CNR-Consiglio Nazionale delle Ricerche, Istituto di Tecnologie Biomediche (ITB-CNR), Area della Ricerca di Pisa, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4184-0175","authenticated-orcid":false,"given":"Daniele","family":"Panetta","sequence":"additional","affiliation":[{"name":"CNR-Consiglio Nazionale delle Ricerche, Istituto di Fisiologia Clinica (IFC-CNR), Area della Ricerca di Pisa, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8516-536X","authenticated-orcid":false,"given":"Paolo","family":"Armanetti","sequence":"additional","affiliation":[{"name":"CNR-Consiglio Nazionale delle Ricerche, Istituto di Fisiologia Clinica (IFC-CNR), Area della Ricerca di Pisa, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6253-3150","authenticated-orcid":false,"given":"Mauro","family":"Quaglierini","sequence":"additional","affiliation":[{"name":"CNR-Consiglio Nazionale delle Ricerche, Istituto di Fisiologia Clinica (IFC-CNR), Area della Ricerca di Pisa, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Alessandro","family":"Zega","sequence":"additional","affiliation":[{"name":"CNR-Consiglio Nazionale delle Ricerche, Istituto di Fisiologia Clinica (IFC-CNR), Area della Ricerca di Pisa, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Raffaella","family":"Mercatelli","sequence":"additional","affiliation":[{"name":"CNR-Consiglio Nazionale delle Ricerche, Istituto di Tecnologie Biomediche (ITB-CNR), Area della Ricerca di Pisa, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8478-7370","authenticated-orcid":false,"given":"Emilia","family":"Bramanti","sequence":"additional","affiliation":[{"name":"CNR-Consiglio Nazionale delle Ricerche, Istituto di Chimica dei Composti OrganoMetallici (ICCOM-CNR), SS di Pisa, Area della Ricerca di Pisa, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3293-9616","authenticated-orcid":false,"given":"Luca","family":"Menichetti","sequence":"additional","affiliation":[{"name":"CNR-Consiglio Nazionale delle Ricerche, Istituto di Fisiologia Clinica (IFC-CNR), Area della Ricerca di Pisa, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"funding-acquisition","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1866-5898","authenticated-orcid":false,"given":"Giorgia","family":"Maroni","sequence":"additional","affiliation":[{"name":"CNR-Consiglio Nazionale delle Ricerche, Istituto di Tecnologie Biomediche (ITB-CNR), Area della Ricerca di Pisa, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4612-3105","authenticated-orcid":false,"given":"Elena","family":"Levantini","sequence":"additional","affiliation":[{"name":"CNR-Consiglio Nazionale delle Ricerche, Istituto di Tecnologie Biomediche (ITB-CNR), Area della Ricerca di Pisa, 56124 Pisa, Italy"},{"name":"Fondazione Pisana per la Scienza ONLUS (FPS), San Giuliano Terme, 56017 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"funding-acquisition","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"O\u2019Leary, C., Gasper, H., Sahin, K.B., Tang, M., Kulasinghe, A., Adams, M.N., Richard, D.J., and O\u2019Byrne, K.J. (2020). Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC). Pharmaceuticals, 13.","DOI":"10.3390\/ph13100273"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","article-title":"Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment","volume":"94","author":"Duma","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1158\/0008-5472.CAN-18-1281","article-title":"Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer","volume":"79","author":"Murtuza","year":"2019","journal-title":"Cancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.semcancer.2022.04.002","article-title":"EGFR signaling pathway as therapeutic target in human cancers","volume":"85","author":"Levantini","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1056\/NEJMra0802714","article-title":"Lung cancer","volume":"359","author":"Herbst","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"216062","DOI":"10.1016\/j.canlet.2023.216062","article-title":"Novel EGFR-mutant mouse models of lung adenocarcinoma reveal adaptive immunity requirement for durable osimertinib response","volume":"556","author":"Kleczko","year":"2023","journal-title":"Cancer Lett."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1158\/2767-9764.CRC-23-0161","article-title":"Correction: Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment","volume":"4","author":"Maroni","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1001\/jamaoncol.2018.2969","article-title":"Assessment of Resistance Mechanisms and Clinical Implications in Patients with EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib","volume":"4","author":"Oxnard","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.lungcan.2018.12.010","article-title":"Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M","volume":"128","author":"Zhao","year":"2019","journal-title":"Lung Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jtho.2023.09.1453","article-title":"Real-World Genomic Profile of EGFR Second-Site Mutations and Other Osimertinib Resistance Mechanisms and Clinical Landscape of NSCLC Post-Osimertinib","volume":"19","author":"Rotow","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.lungcan.2019.10.021","article-title":"Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib","volume":"141","author":"Zhao","year":"2020","journal-title":"Lung Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nature10762","article-title":"Clonal evolution in cancer","volume":"481","author":"Greaves","year":"2012","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2020.03.007","article-title":"Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance","volume":"37","author":"Marusyk","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"471","DOI":"10.21037\/tlcr.2020.03.35","article-title":"EGFR mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients","volume":"9","author":"Zheng","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.2147\/CMAR.S207170","article-title":"Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: A prospective observational study","volume":"11","author":"Igawa","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Wang, C., Zhao, K., Hu, S., Li, M., and Song, Y. (2021). Patterns and Treatment Strategies of Osimertinib Resistance in T790M-Positive Non-Small Cell Lung Cancer: A Pooled Analysis. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.600844"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Yu, J.Y., Yu, S.F., Wang, S.H., Bai, H., Zhao, J., An, T.T., Duan, J.C., and Wang, J. (2016). Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21. Chin. J. Cancer, 35.","DOI":"10.1186\/s40880-016-0086-2"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Braschel, C., Fabikan, H., Rodriguez, V.M., Hochmair, M.J., Illini, O., Ay, L., Weinlinger, C., Krainer-Jacobs, J., Muser, N., and Valipour, A. (2026). Clinical Impact of EGFR Mutation Subtypes on Treatment Outcomes in Advanced Non-Small Cell Lung Cancer: An Austrian Real-World Study. Cancers, 18.","DOI":"10.3390\/cancers18020278"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Li, Y., Li, G., Zheng, Z., Wen, W., Zhao, H., Liu, X., Xie, J., and Han, L. (2024). Benefits of osimertinib treat a lung adenocarcinoma patient with germline EGFR T790M, somatic EGFR 19-Del, TP53 and PIK3CA mutations. Hered. Cancer Clin. Pract., 22.","DOI":"10.1186\/s13053-024-00286-4"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nm.4040","article-title":"Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition","volume":"22","author":"Hata","year":"2016","journal-title":"Nat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"10690","DOI":"10.1038\/ncomms10690","article-title":"Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells","volume":"7","author":"Ramirez","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","article-title":"Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future","volume":"168","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41586-023-05783-5","article-title":"Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx","volume":"616","author":"Frankell","year":"2023","journal-title":"Nature"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1634\/theoncologist.2011-0385","article-title":"EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas","volume":"17","author":"Chen","year":"2012","journal-title":"Oncologist"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/1759-7714.12991","article-title":"Mixed response to osimertinib and the beneficial effects of additional local therapy","volume":"10","author":"Shinno","year":"2019","journal-title":"Thorac. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Rossi, A., and Galetta, D. (2022). Systemic Therapy for Oligoprogression in Patients with Metastatic NSCLC Harboring Activating EGFR Mutations. Cancers, 14.","DOI":"10.3390\/cancers14030832"},{"key":"ref_31","first-page":"445","article-title":"EGFR mutation heterogeneity and mixed response to EGFR tyrosine kinase inhibitors of non small cell lung cancer: A clue to overcoming resistance","volume":"2","author":"Remon","year":"2013","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"106034","DOI":"10.1016\/j.esmoop.2025.106034","article-title":"Global advances and future directions in lung cancer care: Expert consensus and strategic priorities","volume":"11","author":"Meyer","year":"2026","journal-title":"ESMO Open"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41392-024-01891-4","article-title":"Drug tolerant persister cell plasticity in cancer: A revolutionary strategy for more effective anticancer therapies","volume":"9","author":"He","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Gomatou, G., Syrigos, N., and Kotteas, E. (2023). Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options. Cancers, 15.","DOI":"10.3390\/cancers15030841"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Maroni, G., Cabrera San Millan, E., Mercatelli, R., Chiodi, A., Campanella, B., Onor, M., Modeo, L., Braccini, G., Cercignani, G., and Ali, A. (2025). Reprogramming of Osimertinib-Resistant EGFR-mutant NSCLC: The Pyruvate-Acetaldehyde-Acetate Pathway As a Key Driver of Resistance. bioRxiv.","DOI":"10.1101\/2025.06.27.661913"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Maroni, G., Cabrera San Millan, E., Campanella, B., Onor, M., Cercignani, G., Muscatello, B., Braccini, G., Mercatelli, R., Chiodi, A., and Mosca, E. (2025). Deciphering the Role of Acetate in Metabolic Adaptation and Osimertinib Resistance in Non-Small Cell Lung Cancer. bioRxiv.","DOI":"10.1101\/2025.07.04.663159"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/annonc\/mdt573","article-title":"Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing","volume":"25","author":"Yu","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Sheng, J., Kang, S., Fang, W., Yan, Y., Hu, Z., Hong, S., Wu, X., Qin, T., and Liang, W. (2014). Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: A meta-analysis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0107161"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/cas.12996","article-title":"Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy","volume":"107","author":"Kobayashi","year":"2016","journal-title":"Cancer Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.lungcan.2022.01.014","article-title":"Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer","volume":"166","author":"Huang","year":"2022","journal-title":"Lung Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"100007","DOI":"10.1016\/j.xcrm.2020.100007","article-title":"Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer","volume":"1","author":"Roper","year":"2020","journal-title":"Cell Rep. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1126\/science.959840","article-title":"The clonal evolution of tumor cell populations","volume":"194","author":"Nowell","year":"1976","journal-title":"Science"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Foo, J., and Michor, F. (2009). Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies. PLoS Comput. Biol., 5, Erratum in PLoS Comput. Biol. 2009, 5.","DOI":"10.1371\/annotation\/d5844bf3-a6ed-4221-a7ba-02503405cd5e"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrclinonc.2015.175","article-title":"The influence of subclonal resistance mutations on targeted cancer therapy","volume":"13","author":"Schmitt","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.7150\/ijbs.72534","article-title":"Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance","volume":"18","author":"Zhang","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1101\/gad.1417406","article-title":"Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors","volume":"20","author":"Politi","year":"2006","journal-title":"Genes Dev."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Regales, L., Balak, M.N., Gong, Y., Politi, K., Sawai, A., Le, C., Koutcher, J.A., Solit, D.B., Rosen, N., and Zakowski, M.F. (2007). Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PLoS ONE, 2.","DOI":"10.1371\/journal.pone.0000810"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1023\/A:1013986627504","article-title":"Conditional gene expression in the respiratory epithelium of the mouse","volume":"11","author":"Perl","year":"2002","journal-title":"Transgenic Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"EMMM201708313","DOI":"10.15252\/emmm.201708313","article-title":"Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancer","volume":"10","author":"Ali","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.7150\/thno.38729","article-title":"Targeting microtubules sensitizes drug resistant lung cancer cells to lysosomal pathway inhibitors","volume":"10","author":"Chin","year":"2020","journal-title":"Theranostics"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"6157","DOI":"10.7150\/thno.35805","article-title":"CAV1\u2014GLUT3 signaling is important for cellular energy and can be targeted by Atorvastatin in Non-Small Cell Lung Cancer","volume":"9","author":"Ali","year":"2019","journal-title":"Theranostics"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/17\/7727\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T12:21:09Z","timestamp":1788524469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/17\/7727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":51,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ijms27177727"],"URL":"https:\/\/doi.org\/10.3390\/ijms27177727","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]}}}